Literature DB >> 21907615

Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.

Kwangsoo Lyoo1, Myeong Jun Song, Wonhee Hur, Jung Eun Choi, Sung Woo Hong, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Sang Wook Choi, Eui-Cheol Shin, Seung Kew Yoon.   

Abstract

BACKGROUND: Single nucleotide polymorphisms (SNPs) near the IL28B gene have recently been described as predictors of antiviral therapy responses in patients with hepatitis C virus (HCV) genotype-1.
OBJECTIVES: The aim of this study was to investigate the association between genetic variation near the IL28B gene and treatment outcome prediction in Korean patients receiving peg-interferon (PEG-IFN) plus ribavirin therapy. STUDY
DESIGN: The allelic discrimination assay by Taqman real-time PCR was developed to determine genotypes of SNPs, rs12979860 and rs8099917, which were analyzed in 65 Korean patients with HCV genotype-1.
RESULTS: For rs12979860, the frequency of patients with sustained virological response (SVR) was 70.2% in those with the CC genotype and 25% in those with the CT genotype. Early virological response (EVR) in patients with the CC genotype (84.2%) was higher than in those with the CT genotype (25.0%). For rs8099917, patients with the TT genotype showed significantly higher in SVR and EVR than those with the TG/GG genotype (69.6% vs 33.3% and 82.1% vs 44.4%, respectively). With regards to the genotype frequency of the SNPs, the homozygous genotypes for rs12979860 (CC) or rs8099917 (TT) in Korean patients showed a significantly higher frequency as compared with other ethnicities; Caucasians, African-American, Hispanic, and Japanese.
CONCLUSIONS: These results demonstrate that the genotypes rs12979860 CC and rs8099917 TT were more frequently observed in Korean patients compared to other ethnicities, and suggest that the genetic characteristics of patients may be prognostic factor that predicts antiviral response to PEG-IFN therapy for chronic hepatitis C.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907615     DOI: 10.1016/j.jcv.2011.08.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  26 in total

Review 1.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

2.  Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Authors:  Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

3.  PharmGKB summary: peginterferon-α pathway.

Authors:  Scott R Shuldiner; Li Gong; Andrew J Muir; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-09       Impact factor: 2.089

4.  The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial.

Authors:  Jung Hyun Kwon; Si Hyun Bae; Youn Jae Lee; Jin-Woo Lee; Young Seok Kim; Jae Seok Hwang; Won Young Tak; Jeong Won Jang; Byung Seok Lee; June Sung Lee; Chun Kyon Lee; Soon Koo Baik; Neung Hwa Park; Tae Hee Lee; Dong Joon Kim; Jae-Seok Choi; Jae-Gook Shin; Hyeon Woo Yim
Journal:  Hepatol Int       Date:  2013-10-23       Impact factor: 6.047

Review 5.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

6.  A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.

Authors:  Young-Suk Lim; Sang Hoon Ahn; Kwan Sik Lee; Seung Woon Paik; Youn-Jae Lee; Sook-Hyang Jeong; Ju-Hyun Kim; Seung Kew Yoon; Hyung Joon Yim; Won Young Tak; Sang-Young Han; Jenny C Yang; Hongmei Mo; Kimberly L Garrison; Bing Gao; Steven J Knox; Phillip S Pang; Yoon Jun Kim; Kwan-Soo Byun; Young Seok Kim; Jeong Heo; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2016-05-20       Impact factor: 6.047

7.  High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.

Authors:  Nae-Yun Heo; Young-Suk Lim; Han Chu Lee; Yung Sang Lee; Kang Mo Kim; Kwan Soo Byun; Kwang-Hyub Han; Kwan Sik Lee; Seung Woon Paik; Seung Kew Yoon; Dong Jin Suh
Journal:  Clin Mol Hepatol       Date:  2013-03-25

8.  Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?

Authors:  Young Kul Jung; Ju Hyun Kim
Journal:  Clin Mol Hepatol       Date:  2013-03-25

Review 9.  Host genetic variants in the pathogenesis of hepatitis C.

Authors:  Monika Rau; Katharina Baur; Andreas Geier
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

10.  Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.

Authors:  Seok Hoo Jeong; Young Kul Jung; Jae Won Yang; Sang Jin Park; Jong Woo Kim; Oh Sang Kwon; Yun Soo Kim; Duck Joo Choi; Ju Hyun Kim
Journal:  Clin Mol Hepatol       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.